Cassava Sciences Cleared in Federal Probe, Shifts Focus to Epilepsy Treatment
20.02.2026 - 12:29:04 | boerse-global.de
Biotechnology firm Cassava Sciences has secured a significant legal victory with the U.S. Department of Justice (DOJ) formally closing its investigation into allegations of scientific misconduct. This move concludes years of regulatory uncertainty that had weighed on the company’s legal standing.
Investors responded with cautious optimism to the news, pushing the company’s share price up by approximately 2.75%. Market observers view the termination of the federal probe as the removal of a major legal overhang that had clouded the stock for an extended period.
The DOJ’s decision to drop its investigation follows the dismissal of a related lawsuit in October 2025. The agency has now permanently Read more...
Hol dir den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt kostenlos anmelden
Jetzt abonnieren.
